Zhang W, Dong Y, Sartor O, et al. - This study was undertaken to investigate the controversial diagnostic utility of single-nucleotide polymorphisms (SNP) for prostate cancer. Researchers examined two datasets collected from Europeans and one from Africans. In this study, about 540,000 SNPs, including 61 risk markers that constitute a panel termed MK-61, were commonly genotyped. The results illustrate that augmented risk SNP panels can enhance prostate cancer prediction for males of European ancestry, particularly those with PSA ≥ 2ng/ml